Roth Capital Keeps Cytokinetics (CYTK) at 'Buy' Following Recent BENEFIT-ALS Update
Tweet Send to a Friend
Roth Capital affirms Cytokinetics, Inc. (Nasdaq: CYTK) at Buy with a price target of $13 after the company announced additional ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
